EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Trilaciclib: A Novel Approach to Mitigate Chemotherapy-Induced Myelosuppression in Cancer Treatment

Mayank Kapoor, Amit Sehrawat, Deepak Sundriyal

Indian Journal of Medical and Paediatric Oncology · 01.08.2024 · 45 (04) · 320-322

DOI: 10.1055/s-0044-1786017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Medical and Paediatric Oncology, erschienen am 01.08.2024. Verfasst von Mayank Kapoor und 2 weiteren Autor:innen. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Trilaciclib, a novel cyclin-dependent kinase 4/6 inhibitor, has demonstrated the ability to protect bone marrow from chemotherapy toxicity, improving patients' quality of life (QoL). This review describes the mechanism of action, efficacy, and toxicity profile of trilaciclib. Trilaciclib halts retinoblastoma protein phosphorylation during the early G1 phase, preventing the transition from the G1/S phase and inducing the cell cycle arrest in the G1 phase, which protects the hematopoietic cell lineages. Trilaciclib is indicated by the United States Food and Drug Administration and National Comprehensive Cancer Network to decrease the incidence of chemotherapy-induced myelosuppression in adult patients before a platinum/etoposide or topotecan containing regimen for extensive stage small cell lung cancer. Its ease of administration as an intravenous infusion, given before starting chemotherapy, and the favorable side effect profile make it a better-tolerated drug, improving patient QoL.

Zitieren

APA

Kapoor, M., Sehrawat, A., & Sundriyal, D. (2024). Trilaciclib: A Novel Approach to Mitigate Chemotherapy-Induced Myelosuppression in Cancer Treatment. Indian Journal of Medical and Paediatric Oncology, 45(04), 320-322. https://doi.org/10.1055/s-0044-1786017

Vancouver

Kapoor M, Sehrawat A, Sundriyal D. Trilaciclib: A Novel Approach to Mitigate Chemotherapy-Induced Myelosuppression in Cancer Treatment. Indian Journal of Medical and Paediatric Oncology. 2024;45(04):320-322. doi:10.1055/s-0044-1786017

BibTeX
@article{Kapoor2024,
  author = {Kapoor, Mayank and Sehrawat, Amit and Sundriyal, Deepak},
  title = {Trilaciclib: A Novel Approach to Mitigate Chemotherapy-Induced Myelosuppression in Cancer Treatment},
  journal = {Indian Journal of Medical and Paediatric Oncology},
  year = {2024},
  volume = {45},
  number = {04},
  pages = {320--322},
  doi = {10.1055/s-0044-1786017}
}
Kostenlos starten →